Rapastinel

Generic Name
Rapastinel
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H31N5O6
CAS Number
117928-94-6
Unique Ingredient Identifier
6A1X56B95E
Background

Rapastinel has been used in trials studying the treatment of Depressive Disorder, Major and Obsessive-Compulsive Disorder (OCD).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)

First Posted Date
2019-02-27
Last Posted Date
2019-07-19
Lead Sponsor
Naurex, Inc, an affiliate of Allergan plc
Registration Number
NCT03855865

Assessment of Effect of Rapastinel on Driving Performance

First Posted Date
2019-01-24
Last Posted Date
2019-07-11
Lead Sponsor
Naurex, Inc, an affiliate of Allergan plc
Target Recruit Count
107
Registration Number
NCT03814733
Locations
πŸ‡ΊπŸ‡Έ

Collaborative Neuroscience Network, San Clemente, California, United States

πŸ‡¨πŸ‡¦

Algorithme Pharma, Aurora, Ontario, Canada

Assessment of Abuse Potential of Rapastinel in Humans

First Posted Date
2019-01-10
Last Posted Date
2019-05-16
Lead Sponsor
Naurex, Inc, an affiliate of Allergan plc
Target Recruit Count
72
Registration Number
NCT03799900
Locations
πŸ‡ΊπŸ‡Έ

Vince and Associates Clinical Research Inc, Overland Park, Kansas, United States

Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)

Phase 3
Terminated
Conditions
Depressive Disorder, Major
Interventions
Drug: Rapastinel
Drug: Placebo
First Posted Date
2018-09-18
Last Posted Date
2020-07-28
Lead Sponsor
Naurex, Inc, an affiliate of Allergan plc
Target Recruit Count
50
Registration Number
NCT03675776
Locations
πŸ‡ΈπŸ‡°

MENTUM, s.r.o., Bratislava, Slovakia

πŸ‡―πŸ‡΅

Yokohama Onoecho Clinic, Yokohama-shi, Japan

πŸ‡―πŸ‡΅

Medical corporation Sato-Kai Yuge Hospital, Kumamoto-shi, Japan

and more 20 locations

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

Phase 3
Terminated
Conditions
Depressive Disorder, Major
Interventions
Drug: Rapastinel
First Posted Date
2018-09-12
Last Posted Date
2020-07-17
Lead Sponsor
Naurex, Inc, an affiliate of Allergan plc
Target Recruit Count
230
Registration Number
NCT03668600
Locations
πŸ‡ΊπŸ‡Έ

CITrials, Riverside, California, United States

πŸ‡ΊπŸ‡Έ

Institute for Advanced Medical Research, Atlanta, Georgia, United States

πŸ‡ΊπŸ‡Έ

The Ohio State University Department of Psychiatry, Columbus, Ohio, United States

and more 70 locations

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

Phase 3
Terminated
Conditions
Depressive Disorder, Major
Interventions
Drug: Placebo
Drug: Rapastinel
First Posted Date
2018-08-03
Last Posted Date
2020-10-09
Lead Sponsor
Naurex, Inc, an affiliate of Allergan plc
Target Recruit Count
363
Registration Number
NCT03614156
Locations
πŸ‡ΊπŸ‡Έ

Woodland International Research Group, Little Rock, Arkansas, United States

πŸ‡ΊπŸ‡Έ

Synergy Research San Diego, National City, California, United States

πŸ‡ΊπŸ‡Έ

NRC Research Institute, Orange, California, United States

and more 49 locations

Study of Rapastinel as Monotherapy in Patients With MDD

Phase 3
Terminated
Conditions
Depressive Disorder, Major
Interventions
Drug: Placebo
Drug: Rapastinel
First Posted Date
2018-06-18
Last Posted Date
2020-09-01
Lead Sponsor
Naurex, Inc, an affiliate of Allergan plc
Target Recruit Count
439
Registration Number
NCT03560518
Locations
πŸ‡ΊπŸ‡Έ

California Pharmaceutical Research Institute, Inc., Anaheim, California, United States

πŸ‡ΊπŸ‡Έ

Research Centers of America, LLC, Hollywood, Florida, United States

πŸ‡ΊπŸ‡Έ

Atlanta Center for Medical Research, Atlanta, Georgia, United States

and more 37 locations

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

Phase 2
Terminated
Conditions
Depressive Disorder, Major
Interventions
Drug: Placebo
Drug: Rapastinel
First Posted Date
2017-11-24
Last Posted Date
2020-08-14
Lead Sponsor
Naurex, Inc, an affiliate of Allergan plc
Target Recruit Count
138
Registration Number
NCT03352453
Locations
πŸ‡ΊπŸ‡Έ

CBH Health, Gaithersburg, Maryland, United States

πŸ‡ΊπŸ‡Έ

Collaborative NeuroScience Network, LLC, Garden Grove, California, United States

πŸ‡ΊπŸ‡Έ

Research Centers of America, LLC, Oakland Park, Florida, United States

and more 14 locations

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

Phase 3
Completed
Conditions
Depressive Disorder, Major
Interventions
Drug: Rapastinel
First Posted Date
2016-12-23
Last Posted Date
2020-06-22
Lead Sponsor
Naurex, Inc, an affiliate of Allergan plc
Target Recruit Count
617
Registration Number
NCT03002077
Locations
πŸ‡ΊπŸ‡Έ

Innova Clinical Trials Inc., Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

International Research Associates, LLC, Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

PCSD Feighner Research, San Diego, California, United States

and more 121 locations

A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

First Posted Date
2016-11-01
Last Posted Date
2020-03-09
Lead Sponsor
Naurex, Inc, an affiliate of Allergan plc
Target Recruit Count
1304
Registration Number
NCT02951988
Locations
πŸ‡ΊπŸ‡Έ

Atlanta Center for Medical Research, Atlanta, Georgia, United States

πŸ‡ΊπŸ‡Έ

Northwest Behavioral Research Center, Marietta, Georgia, United States

πŸ‡ΊπŸ‡Έ

Global Medical Institute, LLC, Princeton, New Jersey, United States

and more 128 locations
Β© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy